A former sleep clinic owner pleaded guilty to health care fraud and aggravated identity theft charges today for submitting over $1 million in fraudulent claims for sleep studies to Medicare, according to a release from the US Attorney’s Office, Eastern District of California.
Jazz Pharmaceuticals is challenging the FDA in district court over the FDA’s recent approval of a competing new narcolepsy drug, Lumryz.
Glidewell’s Silent Nite sleep appliance is now eligible for Medicare reimbursement, making the mandibular advancement device more accessible to patients with OSA.
The approval of the extended-release formulation of sodium oxybate allows for uninterrupted sleep and full treatment benefits in a single bedtime dose for people with narcolepsy.
The Gazette: Peggy Waters reported being diagnosed with sleep apnea in 2014 while working at the university.
As part of the settlement, Regional Home Care will refund MassHealth members, vacate millions in judgments against consumers, and reform its debt collection practices.
The sleep techs turned their attention to the equipment, rather than the patient, when reacting to the sensor data, according to the family's attorney. Healthcare professionals must treat the patient, not the equipment, sources say.
Pear Therapeutics, the company behind Somryst, is not accepting new prescriptions for its products, nor will refills be dispensed at this time, according to a statement on the company’s website.
Challenger Motor Freight will launch a voluntary sleep apnea education and screening program incorporating Resonea's DROWZLE smartphone app.